- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Treatment resistant depression
- Meeting Date: July 2021
- Public Summary Document (PSD) July 2021 PBAC Meeting - (PDF 1710KB)
- Public Summary Document (PSD) July 2021 PBAC Meeting - (Word 518KB)
Esketamine – July 2021
Esketamine: Nasal spray solution 28 mg; Spravato®
Last updated
12 November 2021